Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03087487 · ClinicalTrials.gov registry record
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
A clinical trial of Non-valvular Atrial Fibrillation, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 466,991
- Enrollment target
- 1
- Study location
NCT03087487 is a study of Non-valvular Atrial Fibrillation that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 466,991 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03087487, a study of Non-valvular Atrial Fibrillation, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 466,991 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin or apixaban or dabigatran or rivaroxaban treatment.
Conditions Studied
Study Locations (1)
Michigan
- Local Institution - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466,991 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2023-03-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03087487
The ClinicalTrials.gov registry entry for NCT03087487 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 466,991 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-valvular Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions.
NCT03087487 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03087487 about?
NCT03087487 is a clinical study titled "Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation". The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin or apixaban or dabigatran or rivaroxaban treatment.
What is the current status of trial NCT03087487?
This trial is currently completed. The enrollment target is 466,991 participants. The study started on 2016-06-01. Estimated completion is 2023-03-08.
What conditions does trial NCT03087487 study?
This clinical trial studies the following conditions: Non-valvular Atrial Fibrillation.
Who is sponsoring clinical trial NCT03087487?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03087487 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-valvular Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.